Drugs / GSK5533524
last change Mar 2026 re-read 3 minutes ago

GSK5533524

Developed for
neoplasm
Investigated by
GlaxoSmithKline

Trials 1

202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07438782 Mar 2026 → Feb 2029 expected neoplasm GlaxoSmithKline Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GSK5533524 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07438782 ↗